Incretin Atlas › Trials › STEP 1
STEP 1
Semaglutide · obesity
Design
- Molecule(s)
- Semaglutide
- Population
- obesity
- Official title
- STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- completed · 2018-06 → 2020-03
- Participants
- 1961
- Duration
- 68 weeks
- Registry
- NCT03548935
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| semaglutide 2.4 mg | obesity | 68 | 1961 | −16.9 % vs −2.4 % Δ −14.5 pp | −14.9 % vs −2.4 % Δ −12.5 pp | −0.5 vs −0.1 | 7.0 vs 3.1 | — | 44.2 vs 17.4 | 24.8 vs 6.6 | 9.8 vs 6.4 | −6.2 vs −1.1 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- semaglutide 2.4 mg: Per-arm discontinuation is in the supplementary figure only.
Verbatim quotes from the source (5)
- semaglutide 2.4 mg · ae_dc · Table 3
| Adverse events leading to discontinuation of drug or placebo | 92 (7.0) | 123 | 7.2 | 20 (3.1) | 23 | 2.8 |
- semaglutide 2.4 mg · nausea · Table 3
| Nausea | 577 (44.2) | 1068 | 62.6 | 114 (17.4) | 146 | 17.6 |
- semaglutide 2.4 mg · vomiting · Table 3
| Vomiting | 324 (24.8) | 636 | 37.3 | 43 (6.6) | 52 | 6.3 |
- semaglutide 2.4 mg · sae · Table 3
| Serious adverse events | 128 (9.8) | 164 | 9.6 | 42 (6.4) | 53 | 6.4 |
- semaglutide 2.4 mg · hba1c · Table 2 (supportive secondary)
| Glycated hemoglobin — percentage points | -0.45 | -0.15 | -0.29 (-0.32 to -0.26) | | |
Primary sources
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- Novo Nordisk A/S. Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity (STEP 1). ClinicalTrials.gov identifier NCT03548935. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03548935
How to cite this page
Medical Adviser's Group. Incretin Atlas: STEP 1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.